Central administration of murine interferon-α induces depressive-like behavioral, brain cytokine and neurochemical alterations in mice: A mini-review and original experiments

Brain, Behavior, and Immunity

Volumn 31, Issue , 2013, Pages 115-127

  Hayley, Shawn ^a   Scharf, Jeff ^a   Anisman, Hymie ^a  

^a CARLETON UNIVERSITY   (Canada)

Author keywords

Cytokine; Depression; Interferon; Serotonin

Indexed keywords

ALPHA INTERFERON; CORTICOSTERONE; DRUG VEHICLE; INTERLEUKIN 1BETA; INTERLEUKIN 6; MESSENGER RNA; SEROTONIN; SEROTONIN RECEPTOR; TUMOR NECROSIS FACTOR ALPHA;

ANHEDONIA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORTICOSTERONE BLOOD LEVEL; DEPRESSION; DORSAL RAPHE NUCLEUS; DRUG ADMINISTRATION ROUTE; LATERAL BRAIN VENTRICLE; MALE; MOOD DISORDER; MOUSE; NEUROCHEMISTRY; NONHUMAN; PATHOPHYSIOLOGY; PREFRONTAL CORTEX; PRIORITY JOURNAL; PSYCHOMOTOR DISORDER;

ANIMALS; BEHAVIOR, ANIMAL; BRAIN; CORTICOSTERONE; CYTOKINES; DEPRESSION; GENE EXPRESSION; ILLNESS BEHAVIOR; INTERFERON-ALPHA; MALE; MICE; MOTOR ACTIVITY; RECEPTORS, SEROTONIN; RNA, MESSENGER;

EID: 84878132450     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2012.07.023     Document Type: Article

References (110)

1. Ahern G.P. 5-HT and the immune system. Curr. Opin. Pharmacol. 2011, 11:29-33.
2. Albert P.R., François B.L. Modifying 5-HT1A receptor gene expression as a new target for antidepressant therapy. Front Neurosci. 2010, 4:35.
3. Anisman H., Poulter M.O., Gandhi R., Merali Z., Hayley S. Interferon-α effects are exaggerated when administered on a psychosocial stressor backdrop: cytokine, corticosterone and brain monoamine variations. J. Neuroimmunol. 2007, 186:45-53.
4. Anisman H., Du L., Palkovits M., Faludi G., Kovacs G.G., Szontagh-Kishazi P., et al. Serotonin receptor subtype and p11 mRNA expression in stress-relevant brain regions of suicide and control subjects. J. Psychiatry Neurosci. 2008, 33:131-141.
5. Anisman H., Merali Z., Hayley S. Neurotransmitter, peptide and cytokine processes in relation to depressive disorder: comorbidity between depression and neurodegenerative disorders. Prog. Neurobiol. 2008, 85:1-74.
6. 2 and β-adrenergic receptor binding sites in the brain of suicide victims. Arch. Gen. Psychiatry 1990, 47:1038-1046.
7. 1A antagonists. Trends Neurosci. 1996, 19:378-383.
8. Asnis G.M., De la Garza R., Kohn S.R., Reinus J.F., Henderson M., Shah J. IFN-induced depression: a role for NSAIDs. Psychopharmacol. Bull. 2003, 37:29-50.
9. Basterzi A.D., Aydemir C., Kisa C., Aksaray S., Tuzer V., Yazici K., Göka E. IL-6 levels decrease with SSRI treatment in patients with major depression. Hum. Psychopharmacol. 2005, 20:473-476.
10. Beratis S., Katrivanou A., Georgiou S., Monastirli A., Pasmatzi E., Gourzis P., Tsambaos D. Major depression and risk of depressive symptomatology associated with short-term and low-dose interferon-alpha treatment. J. Psychosom. Res. 2005, 58:15-18.
11. Bhagwagar Z., Hinz R., Taylor M., Fancy S., Cowen P., Grasby P. Increased 5-HT(2A) receptor binding in euthymic, medication-free patients recovered from depression: a positron emission study with [(11)C]MDL 100,907. Am. J. Psychiatry 2006, 163:1580-1587.
12. Bluthé R.M., Michaud B., Poli V., Dantzer R. Role of IL-6 in cytokine-induced sickness behavior: a study with IL-6 deficient mice. Physiol. Behav. 2000, 70:367-373.
13. Bonaccorso S., Puzella A., Marino V., Pasquini M., Biondi M., Artini M., Almerighi C., Levrero M., Egyed B., Bosmans E., Meltzer H.Y., Maes M. Immunotherapy with interferon-alpha in patients affected by chronic hepatitis C induces an intercorrelated stimulation of the cytokine network and an increase in depressive and anxiety symptoms. Psychiatry Res. 2001, 15:45-55.
14. Brebner K., Hayley S., Zacharko R., Meral i Z., Anisman H. Synergistic effects of interleukin-1beta, interleukin-6, and tumor necrosis factor-alpha: central monoamine, corticosterone, and behavioral variations. Neuropsychopharmacology 2000, 22:566-580.
15. Cai W., Khaoustov V.I., Xie Q., Pan T., Le W., Yoffe B. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J. Hepatol. 2005, 42:880-887.
16. Capuron L., Miller A.H. Cytokines and psychopathology: lessons from interferon-alpha. Biol. Psychiatry 2004, 1:819-824.
17. Capuron L., Gumnick J.F., Musselman D.L., Lawson D.H., Reemsnyder A., Nemeroff C.B., et al. Neurobehavioural effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology 2002, 26:643-652.
18. Capuron L., Ravaud A., Neveu P.J., Miller A.H., Maes M., Dantzer R. Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy. Mol. Psychiatry 2002, 7:468-473.
19. Capuron L., Neurauter G., Musselman D.L., Lawson D.H., Nemeroff C.B., Fuchs D., Miller A.H. Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment. Biol. Psychiatry 2003, 54:906-914.
20. Capuron L., Ravaud A., Miller A.H., Dantzer R. Baseline mood and psychosocial characteristics of patients developing depressive symptoms during interleukin-2 and/or interferon-alpha cancer therapy. Brain Behav. Immun. 2004, 18:205-213.
21. Capuron L., Fornwalt F.B., Knight B.T., Harvey P.D., Ninan P.T., Miller A.H. Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals?. J. Affect. Disord. 2009, 119:181-185.
22. Craft T.K., DeVries A.C. Role of IL-1 in poststroke depressive-like behavior in mice. Biol. Psychiatry 2006, 60:812-818.
23. Crnic L.S., Segall M.A. Behavioral effects of mouse interferons-alpha and -gamma and human interferon-alpha in mice. Brain Res. 1992, 590:277-284.
24. Curran B., O'Connor J.J. The pro-inflammatory cytokine interleukin-18 impairs long-term potentiation and NMDA receptor-mediated transmission in the rat hippocampus in vitro. Neuroscience 2001, 108:83-90.
25. Dantzer R., O'Connor JC., Freund G.G., Johnson R.W., Kelley K.W. From inflammation to sickness and depression: when the immune system subjugates the brain. Nat. Rev. Neurosci. 2008, 9:46-56.
26. Dantzer R., O'Connor J.C., Lawson M.A., Kelley K.W. Inflammation-associated depression: from serotonin to kynurenine. Psychoneuroendocrinology 2011, 36:426-436.
27. Davis J.M., Weaver J.A., Kohut M.L., Colbert L.H., Ghaffar A., Mayer E.P. Immune system activation and fatigue during treadmill running: role of interferon. Med. Sci. Sports Exerc. 1998, 30:863-868.
28. De La Garza R 2nd., Asnis G.M. The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus. Brain Res. 2003, 4:70-79.
29. De La Garza R 2nd., Asnis G.M., Pedrosa E., Stearns C., Migdal A.L., Reinus J.F., Paladugu R., Vemulapalli S. Recombinant human interferon-alpha does not alter reward behavior, or neuroimmune and neuroendocrine activation in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2005, 29:781-792.
30. Dowlati Y., Herrmann N., Swardfager W., Liu H., Sham L., Reim E.K., Lanctôt K.L. A meta-analysis of cytokines in major depression. Biol. Psychiatry 2010, 67:446-457.
31. Dunn A.L., Crnic L.S. Repeated injections of interferon-alpha A/D in Balb/c mice. Behavioral effects. Brain Behav. Immun. 1993, 7:104-111.
32. Eisenberger N.I., Inagaki T.K., Rameson L.T., Mashal N.M., Irwin M.R. An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage 2009, 47:881-890.
33. Felger J.C., Cole S.W., Pace T.W., Hu F., Woolwine B.J., Doho G.H., Raison C.L., Miller A.H. Molecular signatures of peripheral blood mononuclear cells during chronic interferon-α treatment: relationship with depression and fatigue. Psychol. Med. 2011, 9:1-13.
34. Franklin K.B.J., Paxinos G. A Stereotaxic Atlas of the Mouse Brain 1997, Academic Press, San Diego, CA.
35. Friebe A., Schwarz M.J., Schmid-Wendtner M., Volkenandt M., Schmidt F., Horn M., Janssen G., Schaefer M. Pretreatment levels of sTNF-R1 and sIL-6R are associated with a higher vulnerability for IFN-alpha-induced depressive symptoms in patients with malignant melanoma. J. Immunother. 2007, 30:333-337.
36. Fu X., Zunich S.M., O'Connor J.C., Kavelaars A., Dantzer R., Kelley K.W. Central administration of lipopolysaccharide induces depressive-like behavior in vivo and activates brain indoleamine 2,3 dioxygenase in murine organotypic hippocampal slice cultures. J. Neuroinflammation 2010, 2:7-43.
37. Gibb J., Hayley S., Poulter M.O., Anisman H. Effects of stressors and immune activating agents on peripheral and central cytokines in mouse strains that differ in stressor responsivity. Brain Behav. Immun. 2011, 25:468-482.
38. Gisslinger H., Svoboda T., Clodi M., Gilly B., Ludwig H., Havelec L., Luger A. Interferon-alpha stimulates the hypothalamic-pituitary-adrenal axis in vivo and in vitro. Neuroendocrinol 1993, 57:489-495.
39. Haroon E., Raison C.L., Miller A.H. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2012, 37:137-162.
40. Hashioka S., Klegeris A., Schwab C., Yu S., McGeer P.L. Differential expression of interferon-gamma receptor on human glial cells in vivo and in vitro. J. Neuroimmunol. 2010, 225(1-2):91-99.
41. Hayley S., Poulter M.O., Meral Z., Anisman H. The pathogenesis of clinical depression: stressor- and cytokine-induced alterations of neuroplasticity. Neuroscience 2005, 135:659-678.
42. Howren M.B., Lamkin D.M., Suls J. Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom. Med. 2009, 71:171-186.
43. 2 sites in cortex and amygdala. Brain Res. 1993, 614:37-44.
44. Huang Y., Smith D.E., Ibáñez-Sandoval O., Sims J.E., Friedman W.J. Neuron-specific effects of interleukin-1β are mediated by a novel isoform of the IL-1 receptor accessory protein. Neuroscience 2011, 7:18048-18059.
45. Hulse R.E., Kunkler P.E., Fedynyshyn J.P., Kraig R.P. Optimization of multiplexed bead-based cytokine immunoassays for rat serum and brain tissue. J. Neurosci. Methods 2004, 136:87-98.
46. Kamata M., Higuchi H., Yoshimoto M., Yoshida K., Shimizu T. Effect of single intracerebroventricular injection of alpha-interferon on monoamine concentrations in the rat brain. Eur. Neuropsychopharmacol. 2000, 10:129-132.
47. Kamm K., Vanderkolk W., Lawrence C., Jonker M., Davis A.T. The effect of traumatic brain injury upon the concentration and expression of interleukin-1beta and interleukin-10 in the rat. J. Trauma 2006, 60:152-157.
48. Kaneko N., Kudo K., Mabuchi T., Takemoto K., Fujimaki K., Wati H., Iguchi H., Kanba S., Tezuka H. Suppression of cell proliferation by interferon-alpha through interleukin-1 production in adult rat dentate gyrus. Neuropsychopharmacology 2006, 31:2619-2626.
49. Katafuchi T., Kondo T., Take S., Yoshimura M. Enhanced expression of brain interferon-alpha and serotonin transporter in immunologically induced fatigue in rats. Eur. J. Neurosci. 2005, 22:2817-2826.
50. Kawanokuchi J., Mizuno T., Takeuchi H., Kato H., Wang J., Mitsuma N., Suzumura A. Production of interferon-gamma by microglia. Multiphase Scler. 2006, 12:558-564.
51. Kenis G., Prickaerts J., van Os J., Koek G.H., Robaeys G., Steinbusch H.W., Wichers M. Depressive symptoms following interferon-α therapy: mediated by immune-induced reductions in brain-derived neurotrophic factor?. Int. J. Neuropsychopharmacol. 2011, 4:247-253.
52. Khorooshi R., Owens T. Injury-induced type I IFN signaling regulates inflammatory responses in the central nervous system. J Immunol. 2010, 185(2):1258-1264.
53. Kraus M.R., Schäfer A., Al-Taie O., Scheurlen M. Prophylactic SSRI during interferon alpha re-therapy in patients with chronic hepatitis C and a history of interferon-induced depression. J. Viral Hepat. 2005, 12:96-100.
54. Kraus M.R., Al-Taie O., Schäfer A., Pfersdorff M., Lesch K.P., Scheurlen M. Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology 2007, 132:1279-1286.
55. Kumai T., Tateishi T., Tanaka M., Watanabe M., Shimizu H., Kobayashi S. Effect of interferon-alpha on tyrosine hydroxylase and catecholamine levels in the brain of rats. Life Sci. 2000, 30:663-669.
56. Leonard B., Maes M. Mechanistic explanations how cell-mediated immune activation, inflammation and oxidative and nitrosative stress pathways and their sequels and concomitants play a role in the pathophysiology of unipolar depression. Neurosci. Biobehav. Rev. 2012, 36:764-785.
57. Linthorst A.C. Interactions between corticotropin-releasing hormone and serotonin: implications for the aetiology and treatment of anxiety disorders. Handb. Exp. Pharmacol. 2005, 169:181-204.
58. Litteljohn D., Mangano E., Shukla N., Hayley S. Interferon-gamma deficiency modifies the motor and co-morbid behavioral pathology and neurochemical changes provoked by the pesticide paraquat. Neuroscience 2009, 164:1894-1906.
59. Litteljohn D., Cummings A., Brennan A., Gill A., Chunduri S., Anisman H., Hayley S. Interferon-gamma deficiency modifies the effects of a chronic stressor in mice. Implications for psychological pathology. Brain Behav. Immun. 2010, 24:462-473.
60. Livak K.J., Schmittgen T.D. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 2001, 25:402-408.
61. Loftis J.M., Hauser P. The phenomenology and treatment of interferon induced depression. J. Affect. Disord. 2004, 82:175-190.
62. Loftis J.M., Wall J.M., Pagel R.L., Hauser P. Administration of pegylated interferon-alpha-2a or -2b does not induce sickness behavior in Lewis rats. Psychoneuroendocrinology 2006, 31:1289-1294.
63. Maes M. Evidence for an immune response in major depression: a review and hypothesis. Prog. Neuropsychopharmacol. Biol. Psychiatry 1995, 19:11-38.
64. Maes M., Leonard B.E., Myint A.M., Kubera M., Verkerk R. The new '5-HT' hypothesis of depression: cell-mediated immune activation induces indoleamine 2,3-dioxygenase, which leads to lower plasma tryptophan and an increased synthesis of detrimental tryptophan catabolites (TRYCATs), both of which contribute to the onset of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2011, 35:702-721.
65. Maier S.F., Nguyen K.T., Deak T., Milligan E.D., Watkins L.R. Stress, learned helplessness, and brain interleukin-1 beta. Adv. Exp. Med. Biol. 1999, 461:235-249.
66. Makino M., Kitano Y., Komiyama C., Hirohashi M., Takasuna K. Involvement of central opioid systems in human interferon-alpha induced immobility in the mouse forced swimming test. Br. J. Pharmacol. 2000, 130:1269-1274.
67. Makino M., Kitano Y., Komiyama C., Hirohashi M., Kohno M., Moriyama M., Takasuna K. Human interferon-alpha induces immobility in the mouse forced swimming test: involvement of the opioid system. Brain Res. 2000, 852:482-484.
68. Makino M., Kitano Y., Komiyama C., Takasuna K. Human interferon-alpha increases immobility in the forced swimming test in rats. Psychopharmacology 2000, 148(1):106-110.
69. McNutt M.D., Liu S., Manatunga A., Royster E.B., Raison C.L., Woolwine B.J., Demetrashvili M.F., Miller A.H., Musselman D.L. Neurobehavioral effects of interferon-α in patients with hepatitis-C: symptom dimensions and responsiveness to paroxetine. Neuropsychopharmacology 2012, 37:1444-1454.
70. Menzies R., Phelps C., Wiranowska M., Oliver J., Chen L., Horvath E., Hall N. The effect of interferon-alpha on the pituitary-adrenal axis. J. Interferon Cytokine Res. 1996, 16:619-629.
71. Meyer J.H., McMain S., Kennedy S.H., Korman L., Brown G.M., DaSilva J.N., et al. Dysfunctional attitudes and 5-HT2 receptors during depression and self-harm. Am. J. Psychiatry 2003, 160:90-99.
72. Miller A.H. Norman cousins lecture. Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface. Brain Behav. Immun. 2009, 23:149-158.
73. Miller A.H., Maletic V., Raison C.L. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol. Psychiatry 2009, 65:732-741.
74. Miyahara S., Komori T., Fujiwara R., Shizuya K., Yamamoto M., Ohmori M., Okazaki Y. Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain. Life Sci. 2000, 66:93-98.
75. Morasco B.J., Loftis J.M., Indest D.W., Ruimy S., Davison J.W., Felker B., Hauser P. Prophylactic antidepressant treatment in patients with hepatitis C on antiviral therapy: a double-blind, placebo-controlled trial. Psychosomatics 2010, 51:401-408.
76. Musselman D.L., Lawson D.H., Gumnick J.F., Manatunga A.K., Penna S., Goodkin R.S., Goodkin R.S., Nemeroff C.B., Miller A.H. Paroxetine for the prevention of depression induced by high-dose interferon alfa. N. Engl. J. Med. 2001, 344:961-966.
77. Myint A.M. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012, 279:1375-1385.
78. Myint A.M., Schwarz M.J., Steinbusch H.W., Leonard B.E. Neuropsychiatric disorders related to interferon and interleukins treatment. Metab. Brain Dis. 2009, 24:55-68.
79. Navinés R., Gómez-Gil E., Puig S., Baeza I., De Pablo J., Martín-Santos R. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders. Eur. J. Dermatol. 2009, 19:611-615.
80. Nguyen K.T., Deak T., Owens S.M., Kohno T., Fleshner M., Watkins L.R., Maier S.F. Exposure to acute stress induce brain interleukin-1β protein in the rat. J. Neurosci. 1998, 19:2799-2805.
81. Nishi K., Kanemaru K., Diksic M. A genetic rat model of depression, Flinders sensitive line, has a lower density of 5-HT(1A) receptors, but a higher density of 5-HT(1B) receptors, compared to control rats. Neurochem. Int. 2009, 54:299-307.
82. O'Connor J.C., André C., Wang Y., Lawson M.A., Szegedi S.S., Lestage J., Castanon N., Kelley K.W., Dantzer R. Interferon-gamma and tumor necrosis factor-alpha mediate the upregulation of indoleamine 2,3-dioxygenase and the induction of depressive-like behavior in mice in response to bacillus Calmette-Guerin. J. Neurosci. 2009, 29:4200-4209.
83. Orsal A.S., Blois S.M., Bermpohl D., Schaefer M., Coquery N. Administration of interferon-alpha in mice provokes peripheral and central modulation of immune cells, accompanied by behavioral effects. Neuropsychobiology 2008, 58:211-222.
84. Pan W., Banks W.A., Kastin A.J. Permeability of the blood-brain and blood- spinal cord barriers to interferons. J Neuroimmunol. 1997, 76(1-2):105-111.
85. Pandey G.N., Dwivedi Y., Rizavi H.S., Ren X., Pandey S.C., Pesold C., et al. Higher expression of serotonin 5-HT(2A) receptors in the postmortem brains of teenage suicide victims. Am. J. Psychiatry 2002, 159:419-429.
86. Parnet P., Kelley K.W., Bluthé R.M., Dantzer R. Expression and regulation of interleukin-1 receptors in the brain. Role in cytokines-induced sickness behavior. J. Neuroimmunol. 2002, 125:5-14.
87. Pascoe M.C., Crewther S.G., Carey L.M., Crewther D.P. Inflammation and depression: why poststroke depression may be the norm and not the exception. Int. J. Stroke 2011, 6:128-135.
88. Patten S.B. Psychiatric side effects of interferon treatment. Curr. Drug Saf. 2006, 1:143-150.
89. Patterson A.L., Morasco B.J., Fuller B.E., Indest D.W., Loftis J.M., Hauser P. Screening for depression in patients with hepatitis C using the Beck Depression Inventory-II: do somatic symptoms compromise validity?. Gen. Hosp. Psychiatry 2011, 33:354-362.
90. Raison C.L., Demetrashvili M., Capuron L., Miller A.H. Neuropsychiatric adverse effects of interferon-alpha: recognition and management. CNS Drugs 2005, 19:105-123.
91. Raison C.L., Borisov A.S., Majer M., Drake D.F., Pagnoni G., Woolwine B.J., Vogt G.J., Massung B., Miller A.H. Activation of central nervous system inflammatory pathways by interferon-alpha: relationship to monoamines and depression. Biol. Psychiatry 2009, 65:296-303.
92. Raison C.L., Rye D.B., Woolwine B.J., Vogt G.J., Bautista B.M., Spivey J.R., Miller A.H. Chronic interferon-alpha administration disrupts sleep continuity and depth in patients with hepatitis C: association with fatigue, motor slowing, and increased evening cortisol. Biol. Psychiatry 2010, 68:942-949.
93. Rivest S. Regulation of innate immune responses in the brain. Nat. Rev. Immunol. 2009, 9:429-439.
94. Sammut S., Bethus I., Goodall G., Muscat R. Antidepressant reversal of interferon-alpha-induced anhedonia. Physiol. Behav. 2002, 75:765-772.
95. Sari Y. Serotonin1B receptors: from protein to physiological function and behavior. Neurosci. Biobehav. Rev. 2004, 28:565-582.
96. Sen S., Duman R., Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol. Psychiatry 2008, 64:527-532.
97. Shelton R.C., Sanders-Bush E., Manier D.H., Lewis D.A. Elevated 5-HT 2A receptors in postmortem prefrontal cortex in major depression is associated with reduced activity of protein kinase A. Neuroscience 2009, 158:1406-1415.
98. Shuto H., Kataoka Y., Horikawa T., Fujihara N., Oishi R. Repeated interferon-alpha administration inhibits dopaminergic neural activity in the mouse brain. Brain Res. 1997, 747:348-351.
99. Slavich G.M., O'Donovan A., Epel E.S., Kemeny M.E. Black sheep get the blues: a psychobiological model of social rejection and depression. Neurosci. Biobehav. Rev. 2010, 35:39-45.
100. Spalletta G., Bossù P., Ciaramella A., Bria P., Caltagirone C., Robinson R.G. The etiology of poststroke depression: a review of the literature and a new hypothesis involving inflammatory cytokines. Mol. Psychiatry 2006, 11:984-991.
101. Stoll G., Jander S., Schroeter M. Inflammation and glial responses in ischemic brain lesions. Prog. Neurobiol. 1998, 56:149-171.
102. Trask P.C., Paterson A.G., Esper P., Pau J., Redman B. Longitudinal course of depression, fatigue, and quality of life in patients with high risk melanoma receiving adjuvant interferon. Psychooncology 2004, 13:526-536.
103. Underwood M.D., Kassir S.A., Bakalian M.J., Galfalvy H., Mann J.J., Arango V. Neuron density and serotonin receptor binding in prefrontal cortex in suicide. Int. J. Neuropsychopharmacol. 2011, 9:1-13.
104. Wan Q., Wang X., Wang Y.J., Song L., Wang S.H., Ho W.Z. Morphine suppresses intracellular interferon-alpha expression in neuronal cells. J. Neuroimmunol. 2008, 199:1-9.
105. Wichers M.C., Kenis G., Leue C., Koek G., Robaeys G., Maes M. Baseline immune activation as a risk factor for the onset of depression during interferon-alpha treatment. Biol. Psychiatry 2006, 60:77-79.
106. Wichers M.C., Kenis G., Koek G.H., Robaeys G., Nicolson N.A., Maes M. Interferon-alpha-induced depressive symptoms are related to changes in the cytokine network but not to cortisol. J. Psychosom. Res. 2007, 62:207-214.
107. Wilkinson J., Radkowski M., Eschbacher J.M., Laskus T. Activation of brain macrophages/microglia cells in hepatitis C infection. Gut 2010, 59:1394-1400.
108. Yamada T., Yamanaka I. Microglial localization of alpha-interferon receptor in human brain tissues. Neurosci. Lett. 1995, 189:73-76.
109. Yirmiya R., Pollak Y., Barak O., Avitsur R., Ovadia H., Bette M., Weihe E., Weidsenfeld J. Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology 2001, 24:531-544.
110. Zhu Y., Saito K., Murakami Y., Asano M., Iwakura Y., Seishima M. Early increase in mRNA levels of pro-inflammatory cytokines and their interactions in the mouse hippocampus after transient global ischemia. Neurosci. Lett. 2006, 393:122-126.